Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of leading and best-in-class targeted oncology therapies, today announced financial results for the second quarter ended June 30, 2024 and provided a business update.

“Immunome is focused on establishing and developing a broad pipeline of differentiated oncology therapies. We continue the work needed to prepare AL102 for regulatory submissions, and we are moving toward filing INDs for IM-1021 and IM-3050,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “These programs are supported by a growing team of drug developers, including leaders who have previously contributed to the successful development and commercialization of ADCs and small molecules.”